FDA Approves Lisocabtagene Maraleucel for Second-Line Large B-cell Lymphoma
Pharmacy Times
JUNE 27, 2022
Lisocabtagene maraleucel (liso-cel, Breyanzi; Bristol Myers Squibb) approved for the second-line treatment of patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, and follicular lymphoma grade 3B.
Let's personalize your content